MX2022011896A - Composiciones oftalmicas. - Google Patents

Composiciones oftalmicas.

Info

Publication number
MX2022011896A
MX2022011896A MX2022011896A MX2022011896A MX2022011896A MX 2022011896 A MX2022011896 A MX 2022011896A MX 2022011896 A MX2022011896 A MX 2022011896A MX 2022011896 A MX2022011896 A MX 2022011896A MX 2022011896 A MX2022011896 A MX 2022011896A
Authority
MX
Mexico
Prior art keywords
volume
weight
ophthalmic compositions
dirnethylbenzoate
isoquinoiin
Prior art date
Application number
MX2022011896A
Other languages
English (en)
Inventor
Ramesh Krishnamoorthy
Mitchell A Delong
Jill M Sturdivant
Casey Kopczynski
Cheng - Weng Lin
Original Assignee
Aerie Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerie Pharmaceuticals Inc filed Critical Aerie Pharmaceuticals Inc
Publication of MX2022011896A publication Critical patent/MX2022011896A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación proporciona una composición oftálmica que comprende 2,4-dimetilbenzoato de 4-(3-amino-1-(isoquinolin-6-ilami no)-1-oxopropan-2-il)bencilo o sus sales farmacéuticamente aceptables; aproximadamente 0.01% peso/volumen hasta aproximadamente 1.0% peso/volumen de un amortiguador; y aproximadamente 0.01% peso/volumen hasta aproximadamente 10% peso/volumen de un agente de tonicidad.
MX2022011896A 2016-08-31 2019-02-27 Composiciones oftalmicas. MX2022011896A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662382237P 2016-08-31 2016-08-31

Publications (1)

Publication Number Publication Date
MX2022011896A true MX2022011896A (es) 2022-10-18

Family

ID=59846699

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019002396A MX2019002396A (es) 2016-08-31 2017-08-30 Composiciones oftalmicas.
MX2022011896A MX2022011896A (es) 2016-08-31 2019-02-27 Composiciones oftalmicas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019002396A MX2019002396A (es) 2016-08-31 2017-08-30 Composiciones oftalmicas.

Country Status (10)

Country Link
US (4) US11389441B2 (es)
EP (1) EP3506890A1 (es)
JP (4) JP6907319B2 (es)
KR (2) KR102568082B1 (es)
CN (1) CN109640966A (es)
AU (3) AU2017319520A1 (es)
BR (1) BR112019003945A2 (es)
CA (1) CA3035566A1 (es)
MX (2) MX2019002396A (es)
WO (1) WO2018045091A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
EP3828172A1 (en) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
CN105263494A (zh) 2013-03-15 2016-01-20 爱瑞制药公司 联合治疗
JP6907319B2 (ja) 2016-08-31 2021-07-21 アエリエ ファーマシューティカルズ インコーポレイテッド 眼科用組成物
US10442770B2 (en) 2017-02-02 2019-10-15 Assia Chemical Industries Ltd. Solid state forms of netarsudil mesylate
JP2020515583A (ja) 2017-03-31 2020-05-28 アエリエ ファーマシューティカルズ インコーポレイテッド アリールシクロプロピル−アミノ−イソキノリニルアミド化合物
WO2020056345A1 (en) 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CN110437043A (zh) * 2019-08-24 2019-11-12 黄泳华 由白藜芦醇与前列腺素类似物剂构成的共晶及其在制备抗肿瘤药物中的用途

Family Cites Families (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2623228C3 (de) 1976-05-24 1981-09-10 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren N-Acyl-substituierte Benzamide, Verfahren zu ihrer Herstellung und Arzneimittel, enthaltend solche Benzamide
JPS5587771A (en) 1978-12-27 1980-07-02 Teikoku Hormone Mfg Co Ltd 1-phenylisoquinoline derivative
US4456757A (en) 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
JPS5993054A (ja) 1982-11-18 1984-05-29 Asahi Chem Ind Co Ltd イソキノリンスルホン酸アミド誘導体
DK8386A (da) 1986-01-15 1987-07-09 Tpo Pharmachim Nye n-substituerede 1-benzyl-2-carbamoyltetrahydroisoquinoliner og fremgangsmaade til fremstilling af samme
AU600992B2 (en) 1986-10-28 1990-08-30 Smith Kline & French Laboratories Limited Tetrahydroisoquinolin-2-yl derivatives of carboxylic acids
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5591887A (en) 1987-04-30 1997-01-07 R-Tech Ueno, Ltd. Prostaglandins of the F series
JPH01139528A (ja) 1987-11-24 1989-06-01 Showa Denko Kk 抗潰瘍剤
EP0569046B1 (en) 1988-09-06 2002-11-13 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
DK0389995T3 (da) 1989-03-28 1995-07-03 Nisshin Flour Milling Co Isoquinolinderivater til behandling af glaukom eller okular hypertension
KR920008026A (ko) 1990-10-24 1992-05-27 오노 화아마슈티칼 캄파니 리미팃드 이소퀴놀리논 유도체 또는 이의 무독성 산부가염 또는 이의 수화물, 이의 제조방법 및 이를 포함하는 약제 조성물
EP0630373A1 (en) 1992-03-12 1994-12-28 Smithkline Beecham Plc Indole derivatives as 5ht1c antagonists
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
DE4332168A1 (de) 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US6124344A (en) 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5462968A (en) 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US5698733A (en) 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
AU7672096A (en) 1995-06-07 1998-06-03 Alcon Laboratories, Inc. Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
US5866602A (en) 1995-12-22 1999-02-02 Alcon Laboratories, Inc. Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
US5814660A (en) 1995-12-22 1998-09-29 Alcon Laboratories, Inc. 9-oxa prostaglandin analogs as ocular hypotensives
ATE273009T1 (de) 1995-12-22 2004-08-15 Alcon Lab Inc Substituierte tetrahydrofuran-analoge von prostaglandinen als augendrucksenkende mittel
US5798380A (en) 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
US6586425B2 (en) 1996-02-21 2003-07-01 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
ATE221048T1 (de) 1996-09-17 2002-08-15 Asahi Glass Co Ltd Fluorierte prostaglandinderivate und medikamente
US6235779B1 (en) 1996-11-12 2001-05-22 Alcon Laboratories, Inc. Use of cis-Δ4 analogs of prostaglandins as ocular hypotensives
AU5258698A (en) 1996-11-12 1998-06-03 Alcon Laboratories, Inc. 15-ketal prostaglandins for the treatment of glaucoma or ocular hypertension
WO1998021181A2 (en) 1996-11-12 1998-05-22 Alcon Laboratories, Inc. 15-fluoro prostaglandins as ocular hypotensives
WO1998020880A2 (en) 1996-11-12 1998-05-22 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
CA2276666A1 (en) 1997-03-07 1998-09-11 Alcon Laboratories, Inc. 13-thia prostaglandins for use in glaucoma therapy
CA2293325C (en) 1997-05-09 2008-09-02 The Mount Sinai School Of Medicine Of The City University Of New York 8-iso-prostaglandins for glaucoma therapy
US5891646A (en) 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
SE9702706D0 (sv) 1997-07-11 1997-07-11 Pharmacia & Upjohn Ab Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
US6048895A (en) 1997-09-09 2000-04-11 The Procter & Gamble Company Aromatic C16-C20 substituted tetrahydro prostaglandins useful as FP agonists
US5977173A (en) 1997-09-09 1999-11-02 Wos; John August Aromatic C16 -C20 -substituted tetrahydro prostaglandins useful as FP agonists
IL134792A0 (en) 1997-09-09 2001-04-30 Procter & Gamble Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
US5877211A (en) 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
WO1999032441A1 (en) 1997-12-22 1999-07-01 Alcon Laboratories, Inc. 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
ES2234270T3 (es) * 1998-07-14 2005-06-16 Alcon Manufacturing, Ltd. Recipientes de polipropileno para productos de prostaglandina.
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US6720175B1 (en) 1998-08-18 2004-04-13 The Johns Hopkins University School Of Medicine Nucleic acid molecule encoding homer 1B protein
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
WO2000071511A2 (en) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
AU5413600A (en) 1999-06-14 2001-01-02 Eli Lilly And Company Compounds
CA2389681C (en) 1999-11-26 2010-11-02 Shionogi & Co., Ltd. Npy y5 antagonist
WO2001047891A1 (fr) 1999-12-28 2001-07-05 Eisai Co., Ltd. Composes heterocylciques contenant des groupes de sulfamide
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
HUP0300544A3 (en) 2000-02-03 2005-03-29 Eisai Co Ltd Pharmaceutical compositions containing integrin expression inhibitors
US6362177B1 (en) 2000-05-16 2002-03-26 Teijin Limited Cyclic amine derivatives and their use as drugs
US6908741B1 (en) 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
US6855690B2 (en) 2000-06-01 2005-02-15 Children's Medical Center Corporation Methods and compositions for treating ocular disorders
US6323228B1 (en) 2000-09-15 2001-11-27 Abbott Laboratories 3-substituted indole angiogenesis inhibitors
AU2002214019B2 (en) 2000-10-17 2007-01-25 Merck Serono Sa Pharmaceutically active sulfanilide derivatives
US7163800B2 (en) 2000-11-03 2007-01-16 Molecular Devices Corporation Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
AU2002245590B2 (en) 2001-03-05 2006-06-29 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
CA2443950C (en) 2001-04-20 2011-10-18 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
AU2003202263A1 (en) 2002-01-10 2003-07-30 Bayer Healthcare Ag Roh-kinase inhibitors
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
AU2003245773A1 (en) 2002-02-15 2003-09-04 Glaxo Group Limited Vanilloid receptor modulators
US20040180889A1 (en) 2002-03-01 2004-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
WO2003075921A2 (en) 2002-03-05 2003-09-18 Transtech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
GB0206876D0 (en) 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
DE60325719D1 (de) 2002-05-13 2009-02-26 Molecular Devices Corp Konstitutiv translozierende zelllinie
TWI350170B (en) 2002-08-29 2011-10-11 Santen Pharmaceutical Co Ltd Treating agent for glaucoma comprising rho kinase inhibitor and prostaglandin
CA2496891A1 (en) 2002-08-30 2004-03-18 Anges Mg, Inc. Novel actin-related cytoskeletal protein lacs
WO2004024717A1 (ja) 2002-09-12 2004-03-25 Kirin Beer Kabushiki Kaisha キナーゼ阻害活性を有するイソキノリン誘導体およびそれを含む医薬
WO2004037784A2 (en) 2002-10-21 2004-05-06 Irm Llc Pyrrolidones with anti-hiv activity
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
PT1632477T (pt) 2003-06-12 2017-04-04 Astellas Pharma Inc Derivado de benzamida ou seu sal
AU2004268621C1 (en) 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
JP2007507547A (ja) 2003-10-06 2007-03-29 グラクソ　グループ　リミテッド キナーゼ阻害剤としての１，７−二置換アザベンゾイミダゾールの調製
DE10348023A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
JP4110324B2 (ja) 2003-10-15 2008-07-02 宇部興産株式会社 新規インダゾール誘導体
SE0400284D0 (sv) 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
JP2005227441A (ja) 2004-02-12 2005-08-25 Konica Minolta Medical & Graphic Inc 光熱写真画像形成材料
US7592357B2 (en) 2004-02-20 2009-09-22 Smithkline Beecham Corporation Compounds
US20080096238A1 (en) 2004-03-30 2008-04-24 Alcon, Inc. High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
DE102004017438A1 (de) 2004-04-08 2005-11-03 Bayer Healthcare Ag Hetaryloxy-substituierte Phenylaminopyrimidine
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
EP1756092A4 (en) 2004-06-17 2009-12-02 Smithkline Beecham Corp NEW INHIBITORS OF RHO-KINASEN
DK1607840T3 (da) 2004-06-18 2015-02-16 Tobii Technology Ab Øjenstyring af et computerapparat
PT1786785E (pt) 2004-08-26 2010-05-21 Pfizer Compostos amino-heteroarilo enantiomericamente puros como inibidores da proteína quinase
EP1810965A4 (en) 2004-10-13 2009-10-28 Eisai R&D Man Co Ltd HYDRAZIDE DERIVATIVES
UY29198A1 (es) 2004-11-09 2006-05-31 Cancer Rec Tech Ltd Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones
GB0425026D0 (en) 2004-11-12 2004-12-15 Biofocus Discovery Ltd Compounds which bind to the active site of protein kinase enzymes
CA2589271A1 (en) 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Urea inhibitors of map kinases
EP1833832A1 (en) 2004-12-31 2007-09-19 GPC Biotech AG Napthyridine compounds as rock inhibitors
US7652041B2 (en) 2005-01-14 2010-01-26 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity
CA2594915A1 (en) 2005-01-28 2006-08-03 Irm Llc Phenyl-substituted pyrrolidones
US20090005321A1 (en) 2005-02-09 2009-01-01 Microbia, Inc. Phenylazetidinone Derivatives
BRPI0610142A2 (pt) 2005-05-25 2011-01-04 Wyeth Corp método para preparar um composto da fórmula (i) ; e método para preparar um ácido da fórmula (vii)
WO2007008926A1 (en) 2005-07-11 2007-01-18 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
US20070135499A1 (en) 2005-07-11 2007-06-14 Aerie Pharmaceuticals, Inc. Hydrazide compounds
EP1951253A2 (en) 2005-10-26 2008-08-06 Cotherix, Inc. Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
TW200738682A (en) 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
CA2629342A1 (en) 2005-12-22 2007-07-05 Alcon Research, Ltd. (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
AR057252A1 (es) 2005-12-27 2007-11-21 Alcon Mfg Ltd Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares
AR058885A1 (es) 2005-12-30 2008-02-27 Novartis Ag Compuestos de piperidina 3,5-sustituidos
ES2426448T3 (es) 2006-01-27 2013-10-23 Shanghai Hengrui Pharmaceutical Co. Ltd. Inhibidores de proteína quinasa de pirrolo[3,2-c]piridin-4-ona 2-indolinona
JP5476559B2 (ja) 2006-02-10 2014-04-23 国立大学法人九州大学 リン酸化酵素の新規基質ポリペプチド
WO2007101204A1 (en) 2006-02-27 2007-09-07 Alcon Research, Ltd. Method of treating glaucoma
MX2008010953A (es) 2006-02-28 2008-09-08 Amgen Inc Derivados de cinolina y quinoxalina como inhibidores de la fosfodiesterasa 10.
JP2007246466A (ja) 2006-03-17 2007-09-27 Osaka Univ 中枢神経損傷に対する嗅粘膜移植にＲｈｏキナーゼ阻害剤を用いた神経機能再建法
US8227480B2 (en) 2006-06-08 2012-07-24 Ube Industries, Ltd. Indazole derivative having spiro ring structure in side chain
WO2008036459A2 (en) 2006-07-20 2008-03-27 Borchardt Allen J Inhibitors of rho kinase
WO2008011557A2 (en) 2006-07-20 2008-01-24 Borchardt Allen J Heteroaryl inhibitors of rho kinase
US20090247552A1 (en) 2006-07-31 2009-10-01 Shirou Sawa Aqueous liquid preparation containing amide compound
ES2729424T3 (es) 2006-09-20 2019-11-04 Aerie Pharmaceuticals Inc Inhibidores de Rho cinasa
WO2008044700A1 (fr) 2006-10-11 2008-04-17 Takeda Pharmaceutical Company Limited INHIBITEUR DE LA GSK-3β
US8949825B1 (en) 2006-10-17 2015-02-03 Manageiq, Inc. Enforcement of compliance policies in managed virtual systems
WO2008049000A2 (en) 2006-10-18 2008-04-24 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
WO2008049919A2 (en) 2006-10-26 2008-05-02 Devgen N.V. Rho kinase inhibitors
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
WO2008079945A2 (en) 2006-12-20 2008-07-03 University Of South Florida Rock inhibitors and uses thereof
AR064420A1 (es) 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
MX2009005966A (es) 2006-12-27 2009-06-15 Sanofi Aventis Derivados de isoquinolona sustituidos con cicloalquilamina.
ATE505458T1 (de) 2006-12-27 2011-04-15 Sanofi Aventis Cycloalkylaminsubstituierte isochinolon- und isochinolinonderivate
BRPI0720859A2 (pt) 2006-12-27 2014-03-25 Sanofi Aventis Derivados de isoquinolina e isoquinolinona substituídos com cicloalquilamina
PT2132194E (pt) 2006-12-27 2011-05-16 Sanofi Aventis Isoquinolinas substitu?das e sua utiliza??o como inibidores de rho-cinase
CA2673916C (en) 2006-12-27 2015-02-17 Sanofi-Aventis Substituted isoquinolone and isoquinolinone derivatives as inhibitors of rho-kinase
RU2009128693A (ru) 2006-12-27 2011-02-10 Санофи-Авентис (Fr) Замещенные производные изохинолина и изохинолинона
BRPI0721180A2 (pt) 2006-12-27 2014-03-18 Sanofi Aventis Derivados de isoquinolina substituídos com cicloalquilamina
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
WO2008105058A1 (ja) 2007-02-27 2008-09-04 Asahi Kasei Pharma Corporation スルホンアミド化合物
US20100063282A1 (en) 2007-04-10 2010-03-11 Boehringer Ingelheim International Gmbh Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions, and Uses Thereof
CN103396409B (zh) 2007-07-05 2015-03-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
DK2217572T3 (da) 2007-11-16 2014-02-03 Vertex Pharma Isoquinoliner som modulatorer af ATP-bindingskassettetransportører
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
PL2315591T3 (pl) 2008-08-15 2016-09-30 Nowe inhibitory pirolowe reduktazy s-nitrozoglutationu jako środki terapeutyczne
EP3828172A1 (en) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
TWI527798B (zh) 2009-06-19 2016-04-01 Western Therapeutics Inst Inc D Substituted isoquinoline derivatives
WO2011085351A2 (en) 2010-01-11 2011-07-14 The Johns Hopkins University Method of treating kcnq related disorders
FR2961694B1 (fr) 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
WO2012030944A2 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinoline and isoquinoline compounds and methods of use thereof
CN104758921A (zh) * 2010-11-08 2015-07-08 希尔洛有限公司 缓冲的眼用组合物以及使用其的方法
WO2012105674A1 (ja) * 2011-02-04 2012-08-09 興和株式会社 緑内障予防又は治療のための薬物療法
JP2013035802A (ja) 2011-08-10 2013-02-21 D Western Therapeutics Institute Inc 緑内障又は高眼圧症の予防又は治療剤
EP2671883A1 (en) 2012-06-05 2013-12-11 Bioprojet New 6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands
JP2014019650A (ja) 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd スルホンアミド化合物とタフルプロストの組み合わせ
CN104884432A (zh) 2012-08-01 2015-09-02 默沙东公司 α7烟碱乙酰胆碱受体调节剂及其用途-I
EP2907802B1 (en) 2012-10-12 2019-08-07 Takeda Pharmaceutical Company Limited Cyclopropanamine compound and use thereof
CN105263494A (zh) * 2013-03-15 2016-01-20 爱瑞制药公司 联合治疗
CA2950238A1 (en) 2014-07-17 2016-01-21 Merck Patent Gmbh Novel naphthyridines and isoquinolines and their use as cdk8/19 inhibitors
US10227343B2 (en) 2015-01-30 2019-03-12 Vanderbilt University Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US9770466B2 (en) 2015-07-02 2017-09-26 Veloce Biopharma, Llc Ophthalmic composition and methods of use
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
WO2018034702A1 (en) 2016-08-19 2018-02-22 Aerie Pharmaceuticals, Inc. Beta-amino-isoquinolinyl amide compounds
JP6907319B2 (ja) * 2016-08-31 2021-07-21 アエリエ ファーマシューティカルズ インコーポレイテッド 眼科用組成物
JP2020515583A (ja) 2017-03-31 2020-05-28 アエリエ ファーマシューティカルズ インコーポレイテッド アリールシクロプロピル−アミノ−イソキノリニルアミド化合物
WO2019191654A1 (en) 2018-03-30 2019-10-03 Aerie Pharmaceuticals, Inc. Mono-(acid) salts of 6-aminoisoquinolines and uses thereof
WO2020056345A1 (en) 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Also Published As

Publication number Publication date
US11707460B2 (en) 2023-07-25
KR102568079B1 (ko) 2023-08-17
KR20200084061A (ko) 2020-07-09
JP2019526629A (ja) 2019-09-19
US20220409607A1 (en) 2022-12-29
AU2022271435A1 (en) 2022-12-22
JP2020172524A (ja) 2020-10-22
AU2017319520A1 (en) 2019-03-07
US11389441B2 (en) 2022-07-19
US20220331308A1 (en) 2022-10-20
MX2019002396A (es) 2019-07-08
US20180055833A1 (en) 2018-03-01
AU2020220146B2 (en) 2022-08-18
US11590123B2 (en) 2023-02-28
KR20190052014A (ko) 2019-05-15
CA3035566A1 (en) 2018-03-08
JP6907319B2 (ja) 2021-07-21
CN109640966A (zh) 2019-04-16
JP2021165285A (ja) 2021-10-14
EP3506890A1 (en) 2019-07-10
US20220304995A1 (en) 2022-09-29
KR102568082B1 (ko) 2023-08-17
BR112019003945A2 (pt) 2019-05-21
AU2020220146A1 (en) 2020-09-10
JP7083005B2 (ja) 2022-06-09
JP7192049B2 (ja) 2022-12-19
WO2018045091A1 (en) 2018-03-08
JP2023016959A (ja) 2023-02-02

Similar Documents

Publication Publication Date Title
MX2022011896A (es) Composiciones oftalmicas.
MX2019001096A (es) Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos.
MX2018011831A (es) Antagonistas solubles de receptor de c5aa(c5ar).
MX2017013535A (es) Metodos y composiciones de limpieza personal concentradas.
MX2017013533A (es) Composiciones de limpieza personal concentradas.
TN2016000081A1 (en) Aminoheteroaryl benzamides as kinase inhibitors
CR20200275A (es) Hidroxiisoxazolinas y derivados de estos
MX2019015744A (es) Composiciones farmaceuticas.
GEP20227373B (en) Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
MX2016014241A (es) Composicion de limpieza que contiene una polieteramina.
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
MX2018004664A (es) Antagonistas de ep4.
MY173573A (en) Pyridin-4-yl derivatives
PH12020550703A1 (en) Sulfonamide compounds and use thereof
MX2017013534A (es) Composiciones concentradas para la limipieza personal y usos.
MX2021001786A (es) Antagonistas de integrina.
MX2019011545A (es) Composiciones celulares y de andamio inyectables.
PH12018501181A1 (en) Phenyl derivatives as cannabinoid receptor 2 agonists
EA201992328A1 (ru) Фармацевтическая композиция, содержащая ленватиниба мезилат
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
GEP20186893B (en) Pyrazines modulators of gpr6
MX2019006939A (es) Preparacion liquida parenteral que comprende compuesto de carbamato.
PH12017501736A1 (en) Indole derivatives
PH12019502852A1 (en) Novel compounds activating the nrf2 pathway